Today: 7 February 2026
Subscribe
Browse Category

NYSE:SDRL News 2 January 2026 - 13 January 2026

Transocean stock today: RIG edges higher before the open as oil slips — what to watch next

Transocean stock today: RIG edges higher before the open as oil slips — what to watch next

NEW YORK, Jan 2, 2026, 09:24 ET — Premarket Transocean Ltd shares rose 0.4% to $4.13 in premarket trading on Friday, a muted move as U.S. markets prepared to open for the first session of 2026. The offshore driller is starting the year with investors still debating what oil prices mean for exploration budgets and long-cycle offshore projects. Those projects can take years to sanction and tend to need stable crude prices before operators commit capital. That matters now because offshore drillers sell time on rigs under multi-month or multi-year contracts, and pricing hinges on how tight the market is.
2 January 2026
····

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop